Educational Symposium
Hope in ADPKD: Innovation in Therapeutics
November 03, 2022 | 12:45 PM - 01:45 PM
Location: Windermere Ballroom X, Hyatt Regency Orlando
Session Description
Polycystic kidney diseases are a group of renal cystic disorders accompanied by a broad array of extrarenal manifestations. The autosomal dominant form, ADPKD, is primarily caused by mutations in the PKD1 and PKD2 genes encoding for polycystin 1 (PC1) and polycystin 2 (PC2). The encoded proteins regulate differentiation, proliferation, survival, apoptosis, and autophagy in renal tubule epithelial cells. Advances in the understanding of multiple molecular pathways involved in the pathophysiology of ADPKD have led to the development of novel treatments, approved or currently under investigation. The approval of tolvaptan, and in Italy of long-acting release octreotide (octreotide-LAR), represents significant hope in the new therapeutic landscape for ADPKD.
This symposium focuses on recent advances in understanding the pathogenic mechanisms underlying ADPKD, as well as current and emerging therapies to slow its progression.
Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.
Learning Objective(s)
- Discuss ADPKD risk stratification and selecting patients for therapy
- Identify emerging and innovative therapies in ADPKD
- Identify therapies for polycystic liver disease
Learning Pathway(s)
- Genetic Diseases and Development
Moderator
- Marie C. Hogan, MBChB, PhD, FASN
Presentations
- Introduction
12:45 PM - 12:55 PM
Marie C. Hogan, MBChB, PhD, FASN
- Diagnosis, Genetic Testing, and Risk Stratification in ADPKD
12:55 PM - 01:15 PM
Meyeon Park, MD, FASN
- Current and Emerging Therapies in ADPKD and Polycystic Liver Disease
01:15 PM - 01:35 PM
Fouad T. Chebib, MD, FASN
- Questions and Answers
01:35 PM - 01:45 PM
